Africa's first end-to-end multi-vaccine manufacturing facility is being built in Cape Town, South Africa, with €75 million from the EIB Group and support from the EU and IFC.
← News
EIB Group, European Commission and IFC back Biovac to build Africa’s first end-to-end multi-vaccine manufacturing site
340 skilled jobs
30–40 Million doses annually
40% cholera supply gap